Cargando…
Microvascular invasion may be the determining factor in selecting TACE as the initial treatment in patients with hepatocellular carcinoma
The aim of this study was to investigate factors affecting tumor necrosis with transcatheter arterial chemoembolization (TACE). Factors associated with early hepatocellular carcinoma recurrence after curative hepatectomy were also evaluated. Data of 51 patients who underwent surgery after a single s...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270609/ https://www.ncbi.nlm.nih.gov/pubmed/34232206 http://dx.doi.org/10.1097/MD.0000000000026584 |
_version_ | 1783720831746048000 |
---|---|
author | Jeong, Joonho Park, Jung Gu Seo, Kwang Ill Ahn, Ji Hyun Park, Jae Chun Yun, Byung Cheol Lee, Sang Uk Lee, Jin Wook Yun, Jong Hyouk |
author_facet | Jeong, Joonho Park, Jung Gu Seo, Kwang Ill Ahn, Ji Hyun Park, Jae Chun Yun, Byung Cheol Lee, Sang Uk Lee, Jin Wook Yun, Jong Hyouk |
author_sort | Jeong, Joonho |
collection | PubMed |
description | The aim of this study was to investigate factors affecting tumor necrosis with transcatheter arterial chemoembolization (TACE). Factors associated with early hepatocellular carcinoma recurrence after curative hepatectomy were also evaluated. Data of 51 patients who underwent surgery after a single session of TACE at a single university hospital were retrospectively analyzed. Factors that might affect tumor necrosis were determined by evaluating the TACE approach and by analyzing computed tomography and TACE findings, pathologic reports, and laboratory findings. In univariate analysis, microvascular invasion (MVI), radiological capsule appearance on the computed tomography, chronic hepatitis B, diabetes mellitus and serum albumin, MVI were significantly associated with tumor necrosis by TACE (P < .02). In multivariate analysis, MVI was the only statistically significant factor in TACE-induced tumor necrosis (P = .001). In univariate and multivariate analysis, MVI was the strongest factor for recurrence-free survival rate within 2 years (P = .008, P = .002). MVI could be a crucial factor in determining TACE as an initial treatment for hepatocellular carcinoma. MVI is also a strong indicator of recurrence within 2 years after curative hepatic resection. |
format | Online Article Text |
id | pubmed-8270609 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-82706092021-07-12 Microvascular invasion may be the determining factor in selecting TACE as the initial treatment in patients with hepatocellular carcinoma Jeong, Joonho Park, Jung Gu Seo, Kwang Ill Ahn, Ji Hyun Park, Jae Chun Yun, Byung Cheol Lee, Sang Uk Lee, Jin Wook Yun, Jong Hyouk Medicine (Baltimore) 4500 The aim of this study was to investigate factors affecting tumor necrosis with transcatheter arterial chemoembolization (TACE). Factors associated with early hepatocellular carcinoma recurrence after curative hepatectomy were also evaluated. Data of 51 patients who underwent surgery after a single session of TACE at a single university hospital were retrospectively analyzed. Factors that might affect tumor necrosis were determined by evaluating the TACE approach and by analyzing computed tomography and TACE findings, pathologic reports, and laboratory findings. In univariate analysis, microvascular invasion (MVI), radiological capsule appearance on the computed tomography, chronic hepatitis B, diabetes mellitus and serum albumin, MVI were significantly associated with tumor necrosis by TACE (P < .02). In multivariate analysis, MVI was the only statistically significant factor in TACE-induced tumor necrosis (P = .001). In univariate and multivariate analysis, MVI was the strongest factor for recurrence-free survival rate within 2 years (P = .008, P = .002). MVI could be a crucial factor in determining TACE as an initial treatment for hepatocellular carcinoma. MVI is also a strong indicator of recurrence within 2 years after curative hepatic resection. Lippincott Williams & Wilkins 2021-07-09 /pmc/articles/PMC8270609/ /pubmed/34232206 http://dx.doi.org/10.1097/MD.0000000000026584 Text en Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/) |
spellingShingle | 4500 Jeong, Joonho Park, Jung Gu Seo, Kwang Ill Ahn, Ji Hyun Park, Jae Chun Yun, Byung Cheol Lee, Sang Uk Lee, Jin Wook Yun, Jong Hyouk Microvascular invasion may be the determining factor in selecting TACE as the initial treatment in patients with hepatocellular carcinoma |
title | Microvascular invasion may be the determining factor in selecting TACE as the initial treatment in patients with hepatocellular carcinoma |
title_full | Microvascular invasion may be the determining factor in selecting TACE as the initial treatment in patients with hepatocellular carcinoma |
title_fullStr | Microvascular invasion may be the determining factor in selecting TACE as the initial treatment in patients with hepatocellular carcinoma |
title_full_unstemmed | Microvascular invasion may be the determining factor in selecting TACE as the initial treatment in patients with hepatocellular carcinoma |
title_short | Microvascular invasion may be the determining factor in selecting TACE as the initial treatment in patients with hepatocellular carcinoma |
title_sort | microvascular invasion may be the determining factor in selecting tace as the initial treatment in patients with hepatocellular carcinoma |
topic | 4500 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270609/ https://www.ncbi.nlm.nih.gov/pubmed/34232206 http://dx.doi.org/10.1097/MD.0000000000026584 |
work_keys_str_mv | AT jeongjoonho microvascularinvasionmaybethedeterminingfactorinselectingtaceastheinitialtreatmentinpatientswithhepatocellularcarcinoma AT parkjunggu microvascularinvasionmaybethedeterminingfactorinselectingtaceastheinitialtreatmentinpatientswithhepatocellularcarcinoma AT seokwangill microvascularinvasionmaybethedeterminingfactorinselectingtaceastheinitialtreatmentinpatientswithhepatocellularcarcinoma AT ahnjihyun microvascularinvasionmaybethedeterminingfactorinselectingtaceastheinitialtreatmentinpatientswithhepatocellularcarcinoma AT parkjaechun microvascularinvasionmaybethedeterminingfactorinselectingtaceastheinitialtreatmentinpatientswithhepatocellularcarcinoma AT yunbyungcheol microvascularinvasionmaybethedeterminingfactorinselectingtaceastheinitialtreatmentinpatientswithhepatocellularcarcinoma AT leesanguk microvascularinvasionmaybethedeterminingfactorinselectingtaceastheinitialtreatmentinpatientswithhepatocellularcarcinoma AT leejinwook microvascularinvasionmaybethedeterminingfactorinselectingtaceastheinitialtreatmentinpatientswithhepatocellularcarcinoma AT yunjonghyouk microvascularinvasionmaybethedeterminingfactorinselectingtaceastheinitialtreatmentinpatientswithhepatocellularcarcinoma |